Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European ...

The presentations will be available on Connect’s website under the publications and presentations section.

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other ...

In early September, RemeGen announced the acceptance by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China of its Biologics License Application (BLA) ...

Behavioral variability is quietly sabotaging clinical trials—but it doesn't have to. Here's how predictive behavioral modeling can improve trial design, reduce dropout, and deliver more inclusive, ...

Unified data also improves AI outputs. For example, by drawing up-to-date information from a variety of an organization’s ...

Hey! I suggest abstracting the user data storage code. The current system could remain as a default option, and plugins could create their own load/save implementation (to avoid adding an extra thing ...

On September 27, 2024, Rwanda reported an outbreak of Marburg virus disease (MVD), after a cluster of cases of viral hemorrhagic fever was detected at two urban hospitals. We report key aspects of the ...

The treatment of non–small cell lung cancer (NSCLC) harboring EGFR mutations has transformed with the introduction of targeted therapies. Despite the success of third-generation tyrosine kinase ...

- Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company ...